Although immune checkpoint inhibitors (ICIs) activate T-cell-mediated immunity by blocking the PD-1/PD-L1 pathway and provide significant clinical benefits, they also result in immune-related adverse events (irAEs), which can include infectious diseases. The gene discussed is PDCD1; the disease is infectious disease.